🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to scientists.

An International Public Health Issue

Gonorrhoea infections are increasing around the world, with data suggesting over 82 million instances per year. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the reality of growing infection rates, escalating drug resistance and the very limited available drugs currently available.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has classified it as a "critical concern". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Secure Authorization

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in recent days for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, also received approval in the same week. This drug, which is additionally indicated for UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a significant shift in the treatment of superbug gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Data and Worldwide Availability

Based on results published in a major medical journal, the new drug eradicated the vast majority of uncomplicated infections. This places it at an similar efficacy with the current standard treatment, which uses a dual-drug approach. The research involved over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the ability to make available and distribute the drug in numerous regions with limited resources.

Doctors treating patients have voiced hope. Having a one-pill regimen like this is seen as a "game-changer" for managing the epidemic. This is considered essential to alleviate the strain of the disease for individuals and to stop the proliferation of untreatable gonorrhoea around the world.